PLSE

Pulse Biosciences Inc

Oct 16 • 09:35AM ET

17.81

+0.52 3.01 %

Healthcare • Medical Instruments & Supplies • USA • NASD

Peers: CUTR IRTC NVRO ITGR IART ANIK NEO MDXG STER TMDX

| Held by: VTI IWM VXF IWO SCHA VTWO VHT IWC ITOT ISMD

Index	RUT	P/E	-	EPS (ttm)	-1.06	Insider Own	81.55%	Shs Outstand	67.28M	Perf Week	-7.48%
Market Cap	1.20B	Forward P/E	-	EPS next Y	-1.44	Insider Trans	0.03%	Shs Float	12.42M	Perf Month	9.46%
Enterprise Value	1.10B	PEG	-	EPS next Q	-0.31	Inst Own	9.00%	Short Float	20.04%	Perf Quarter	17.95%
Income	-68.03M	P/S	-	EPS this Y	-84.33%	Inst Trans	4.17%	Short Ratio	13.34	Perf Half Y	5.45%
Sales	0.00M	P/B	11.47	EPS next Y	-23.08%	ROA	-84.68%	Short Interest	2.49M	Perf YTD	2.30%
Book/sh	1.55	P/C	11.27	EPS next 5Y	-	ROE	-103.50%	52W High	25.00 -28.76%	Perf Year	7.81%
Cash/sh	1.58	P/FCF	-	EPS past 3/5Y	26.13% 16.53%	ROIC	-61.14%	52W Low	13.77 29.38%	Perf 3Y	842.32%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.19% 5.66%	Perf 5Y	13.80%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-33.24%	Oper. Margin	-	ATR (14)	0.93	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.04	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.56	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	12.05	EPS Q/Q	-43.09%	SMA20	-1.90%	Beta	1.81	Target Price	22.00
Payout	-	Debt/Eq	0.08	Sales Q/Q	-	SMA50	6.57%	Rel Volume	0.46	Prev Close	17.29
Employees	75	LT Debt/Eq	0.06	Earnings	Aug 12 AMC	SMA200	4.25%	Avg Volume	186.61K	Price	17.81
IPO	May 18, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	23.54% -	Trades		Volume	5,606	Change	3.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-25	Initiated	Oppenheimer	Outperform	$22
Jul-27-21	Initiated	Stephens	Overweight	$28
Mar-11-21	Initiated	Maxim Group	Buy	$40
Jan-26-21	Reiterated	H.C. Wainwright	Buy	$16 → $40
May-12-20	Upgrade	H.C. Wainwright	Neutral → Buy	$6 → $16
Feb-14-20	Downgrade	H.C. Wainwright	Buy → Neutral	$26 → $6
Feb-25-19	Initiated	H.C. Wainwright	Buy	$27

Today 07:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-13-25 08:14AM	Pulse Biosciences Unveils Promising First-in-Human Data for nPulse (Zacks)
Oct-10-25 07:00AM	Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting (Business Wire) -8.57%
Oct-07-25 07:00AM	Pulse Biosciences Announces Clinical Data Highlighting its nPulse Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting (Business Wire)
Oct-01-25 01:40PM	Pulse Biosciences, Inc. (PLSE) Advances Cardiac Care with FDA-Approved Atrial Fibrillation Trial (Insider Monkey)
07:00AM	Loading…
Sep-17-25 07:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 12:24PM	Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study (Zacks)
Sep-10-25 07:00AM	Pulse Biosciences' nPulse Technology to be Featured at the American Thyroid Association 2025 Annual Meeting (Business Wire)
Sep-09-25 07:00AM	Pulse wins IDE approval; Galvanize pulls in $100M (MedTech Dive)
Sep-08-25 07:00AM	Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation (Business Wire)
Sep-04-25 07:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-02-25 07:00AM	Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study (Business Wire)
Aug-27-25 12:25PM	PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment (Zacks) -6.27%
Aug-26-25 07:00AM	Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid (Business Wire)
Aug-13-25 03:12AM	Pulse Biosciences Inc (PLSE) Q2 2025 Earnings Call Highlights: Navigating Increased Expenses ... (GuruFocus.com) +11.19%
04:05PM	Loading…
Aug-12-25 04:05PM	Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results (Business Wire)
Aug-01-25 07:00AM	Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference (Business Wire)
Jul-29-25 04:05PM	Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025 (Business Wire)
Jul-16-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-23-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-25 03:41AM	Pulse Biosciences Inc (PLSE) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-08-25 04:05PM	Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results (Business Wire)
May-06-25 04:05PM	Pulse Biosciences To Present at the BofA Securities 2025 Health Care Conference (Business Wire)
May-01-25 07:00AM	Pulse Biosciences Nanosecond PFA Technology to be Featured at The American Association for Thoracic Surgery 2025 Annual Meeting (Business Wire)
Apr-25-25 04:05PM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.06%
Apr-24-25 04:05PM	Pulse Biosciences Schedules First Quarter 2025 Financial Results Conference Call for May 8, 2025 (Business Wire) +6.00%
Apr-23-25 07:00AM	Pulse Biosciences Nanosecond PFA Technology to be Featured at The Heart Rhythm Society 2025 Annual Meeting (Business Wire)
Apr-10-25 01:00PM	Pulse Biosciences: Some Key Questions Remain Unanswered (Seeking Alpha)
10:36AM	Pulse Biosciences: Interesting Product, But No Revenue Stream (Seeking Alpha)
Mar-28-25 08:10AM	Q4 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +6.00%
03:03AM	Loading…
03:03AM	Pulse Biosciences Inc (PLSE) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
Mar-27-25 07:46PM	Pulse Biosciences, Inc. (PLSE) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:05PM	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2024 Financial Results (Business Wire)
Mar-26-25 04:05PM	Pulse Biosciences To Present at the 24th Annual Needham Virtual Health Care Conference (Business Wire)
Mar-07-25 08:00AM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2024 Financial Results Conference Call for March 27, 2025 (Business Wire)
Mar-04-25 08:00AM	Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-20-25 04:05PM	Pulse Biosciences To Present at the TD Cowen 45th Annual Health Care Conference (Business Wire)
Feb-05-25 09:42AM	Pulse Biosciences names new CFO, continuing string of C-suite changes (MedTech Dive)
Feb-04-25 08:00AM	Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer (Business Wire) +14.84%
Jan-30-25 08:00AM	Pulse Biosciences Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting (Business Wire)
Jan-21-25 01:03PM	Pulse Biosciences touts positive results from PFA early feasibility study (Medical Device Network) +11.16%
07:00AM	Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360 Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium (Business Wire)
Jan-13-25 07:00AM	Pulse Biosciences Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium (Business Wire)
Jan-10-25 08:00AM	Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer (Business Wire)
Jan-03-25 09:00AM	Pulse Biosciences To Present at the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire) +10.34%
Dec-23-24 04:30PM	Pulse Biosciences, Inc. Announces Planned Redemption of Warrants (Business Wire) +5.34%
Dec-19-24 08:00AM	Pulse Biosciences, Inc. Announces Election to Exercise Company Warrants (Business Wire)
Dec-17-24 08:00AM	Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery (Business Wire)
Oct-31-24 02:25PM	Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association (Business Wire)
01:58PM	Q3 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
05:01AM	Pulse Biosciences Inc (PLSE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Oct-30-24 04:05PM	Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results (Business Wire)
04:02PM	Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology (Business Wire)
Oct-21-24 08:00AM	Pulse Biosciences Schedules Third Quarter 2024 Financial Results Conference Call for October 30, 2024 (Business Wire)
Aug-21-24 07:55AM	Better Cotton Pakistan, PULSE to boost data transparency in cotton farming (Just Style) +13.76%
Aug-13-24 12:38PM	Q2 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) +8.05%
Aug-12-24 04:05PM	Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results (Business Wire)
04:01PM	Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors (Business Wire)
Aug-09-24 06:32AM	Pulse Biosciences launches first-in-human pulsed field ablation trial (Medical Device Network)
Aug-08-24 08:00AM	Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System (Business Wire) +9.74%
Aug-01-24 04:05PM	Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences (Business Wire)
Jul-29-24 04:05PM	Pulse Biosciences Schedules Second Quarter 2024 Financial Results Conference Call for August 12, 2024 (Business Wire) -11.36% -5.95%
Jul-09-24 07:27AM	Pulse drops 510(k) plan for PFA device after FDA requests clinical data (MedTech Dive)
06:53AM	Pulse Biosciences receives breakthrough device status for CellFX system (Medical Device Network)
Jul-08-24 08:00AM	Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation (Business Wire) +28.71%
Jul-03-24 02:44PM	Pulse Biosciences, Inc. Announces the Closing of its Rights Offering (Business Wire)
Jun-28-24 08:00AM	Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering (Business Wire)
Jun-04-24 08:00AM	Pulse Biosciences, Inc. Announces Commencement of Rights Offering (Business Wire)
May-20-24 05:39PM	Pulse Biosciences Moves New Record Date for Rights Offering (MT Newswires) +9.86% +13.40%
04:05PM	Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000 (Business Wire)
May-17-24 06:41AM	Pulse Biosciences names new CEO, reassigns former leader (MedTech Dive)
May-16-24 08:00AM	Pulse Biosciences CellFX Nanosecond Pulsed Field Ablation (nsPFA) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting (Business Wire) +8.68%
May-14-24 05:17PM	Pulse Biosciences Appoints Burke Barrett as President, CEO (MT Newswires) +7.55% -5.59%
04:05PM	Pulse Biosciences Enhances Executive Leadership Team (Business Wire)
May-13-24 09:02AM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:00AM	Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System (Business Wire)
May-08-24 06:06AM	Q1 2024 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -9.21%
03:56AM	Pulse Biosciences Inc (PLSE) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-07-24 09:56PM	PLSE Stock Earnings: Pulse Biosciences Reported Results for Q1 2024 (InvestorPlace)
05:45PM	Pulse Biosciences Reports Q1 2024 Financial Results Amidst Strategic Business Developments (GuruFocus.com)
04:05PM	Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results (Business Wire)
May-02-24 08:00AM	Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 (Business Wire) +5.92%
Apr-28-24 11:59AM	5 ChatGPT Penny Stock Picks Right Now (Insider Monkey)
Apr-24-24 04:05PM	Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024 (Business Wire)
Apr-01-24 04:19PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.27%
Mar-29-24 06:30AM	Q4 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-28-24 10:53PM	PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023 (InvestorPlace) -8.27%
05:51PM	Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023 (GuruFocus.com)
04:12PM	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results (Business Wire)
04:10PM	Pulse Biosciences Announces Plans to Initiate a Rights Offering (Business Wire)
Mar-14-24 04:05PM	Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024 (Business Wire)
Mar-08-24 01:17PM	Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX nsPFA Percutaneous Electrode System (Business Wire)
Feb-14-24 08:00AM	Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX nsPFA 360 Cardiac Catheter First-in-Human Feasibility Study (Business Wire) +12.56%
Jan-31-24 08:00AM	Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium (Business Wire)
Jan-02-24 08:00AM	Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp (Business Wire) -9.97%
Dec-20-23 08:00AM	Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation (nsPFA) Cardiac Catheter (Business Wire) -7.11%
Nov-21-23 08:00AM	Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode (Business Wire) +5.59%
Nov-15-23 04:05PM	Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference (Business Wire) +9.62%
Nov-14-23 12:52PM	Pulse Biosciences, Inc. (NASDAQ:PLSE) Q3 2023 Earnings Call Transcript (Insider Monkey) +7.58%
02:15AM	Q3 2023 Pulse Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Danahy Kevin Patrick	Chief Commercial Officer	Oct 02 '25	Option Exercise	1.53	4,600	7,038	47,898	Oct 07 07:18 PM
Danahy Kevin Patrick	Chief Commercial Officer	Oct 02 '25	Sale	18.53	4,600	85,238	43,298	Oct 07 07:18 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 18 '25	Option Exercise	1.53	20,000	30,600	63,298	Sep 22 09:24 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 19 '25	Option Exercise	1.53	400	612	43,698	Sep 22 09:24 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 18 '25	Sale	18.49	20,000	369,800	43,298	Sep 22 09:24 PM
Danahy Kevin Patrick	Chief Commercial Officer	Sep 19 '25	Sale	18.48	400	7,392	43,298	Sep 22 09:24 PM
UECKER DARRIN	Chief Technology Officer	Sep 17 '25	Option Exercise	4.00	181,534	726,136	284,406	Sep 18 08:44 PM
UECKER DARRIN	Chief Technology Officer	Sep 16 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 18 08:44 PM
UECKER DARRIN	Chief Technology Officer	Sep 16 '25	Sale	16.28	25,000	407,000	122,872	Sep 18 08:44 PM
UECKER DARRIN	Chief Technology Officer	Sep 17 '25	Sale	16.21	20,000	324,200	122,872	Sep 18 08:44 PM
KEVIN DANAHY	Officer	Sep 18 '25	Proposed Sale	16.27	25,000	406,750		Sep 18 04:29 PM
UECKER DARRIN	Chief Technology Officer	Sep 11 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 15 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 12 '25	Option Exercise	4.00	25,000	100,000	147,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 15 '25	Sale	15.77	25,000	394,250	122,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 11 '25	Sale	14.78	25,000	369,500	122,872	Sep 15 09:09 PM
UECKER DARRIN	Chief Technology Officer	Sep 12 '25	Sale	14.32	25,000	358,000	122,872	Sep 15 09:09 PM
DUGGAN ROBERT W	Director	Sep 10 '25	Buy	14.66	34,659	508,101	47,551,200	Sep 12 08:14 PM
DARRIN UECKER	Director	Sep 11 '25	Proposed Sale	14.77	120,000	1,772,400		Sep 11 04:30 PM
UECKER DARRIN	Chief Technology Officer	Jun 12 '25	Sale	16.40	15,000	246,000	137,872	Jun 16 08:23 PM
UECKER DARRIN	Chief Technology Officer	Jun 13 '25	Sale	15.98	15,000	239,700	122,872	Jun 16 08:23 PM
DARRIN UECKER	Officer	Jun 13 '25	Proposed Sale	15.98	15,000	239,740		Jun 13 04:14 PM
DARRIN UECKER	Officer	Jun 12 '25	Proposed Sale	16.40	15,000	246,048		Jun 12 04:25 PM
Barrett Burke Thomas	Former President and CEO	Dec 11 '24	Sale	17.42	50,000	871,000	63,172	Dec 20 05:00 PM
DUGGAN ROBERT W	Director	Dec 13 '24	Buy	17.18	55,256	949,298	42,328,717	Dec 17 08:02 PM
DUGGAN ROBERT W	Director	Dec 12 '24	Buy	17.13	45,404	777,771	42,273,461	Dec 17 06:05 AM
DUGGAN ROBERT W	Director	Dec 11 '24	Buy	17.35	56,054	972,344	42,228,057	Dec 13 07:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLSE

Pulse Biosciences Inc

Upgrade your FINVIZ experience